会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Therapeutic uses of bicyclic ligands of sigma 2 receptor
    • sigma2受体双环配体的治疗用途
    • US08168650B2
    • 2012-05-01
    • US12543647
    • 2009-08-19
    • Robert H. MachRichard HotchkissWilliam HawkinsRebecca AftZhude Tu
    • Robert H. MachRichard HotchkissWilliam HawkinsRebecca AftZhude Tu
    • A01N43/42A61K31/44
    • C07D451/14C07D451/02
    • A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.
    • 公开了一系列N-取代的9-氮杂双环[3.3.1]壬烷-3α-基苯基氨基甲酸酯类似物及其制备方法。 描述了它们对西格玛(&sgr。1和&sgr; 2)受体的亲和力。 两种新化合物N-(9-(4-氨基丁基)-9-氮杂双环[3.3.1]壬烷-3α-基)-N' - (2-甲氧基-5-甲基苯基)氨基甲酸酯和N-(9- 6-氨基己基)-9-氮杂双环[3.3.1]壬烷-3α-基)-N' - (2-甲氧基-5-甲基苯基)氨基甲酸酯显示出对于& 1受体。 所公开的化合物中有生物素化和荧光类似物。 这些化合物可以作为第二受体的探针。 此外,一些公开的化合物可以通过胱天蛋白酶依赖性和半胱天冬酶非依赖性机制诱导凋亡细胞死亡,并且对于治疗肿瘤是有效的。 该化合物可用作化学治疗剂或化学敏化剂,用于治疗各种实体瘤。
    • 2. 发明授权
    • Sigma 2 receptor ligands and therapeutic uses therefor
    • Sigma 2受体配体及其治疗用途
    • US07612085B2
    • 2009-11-03
    • US11776533
    • 2007-07-11
    • Robert H. MachZhude TuWenhua ChuSuwanna VangveravongRichard HotchkissWilliam HawkinsRebecca Aft
    • Robert H. MachZhude TuWenhua ChuSuwanna VangveravongRichard HotchkissWilliam HawkinsRebecca Aft
    • A01N43/42A61K31/44C07D221/02
    • C07D451/14C07D451/02
    • A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.
    • 公开了一系列N-取代的9-氮杂双环[3.3.1]壬烷-3-基苯基氨基甲酸酯类似物及其制备方法。 描述了它们对西格玛(sigma1和sigma2)受体的亲和力。 两种新化合物N-(9-(4-氨基丁基)-9-氮杂双环[3.3.1]壬-3α-基)-N' - (2-甲氧基-5-甲基苯基)氨基甲酸酯和N-(9- 6-氨基己基)-9-氮杂双环[3.3.1]壬-3α-基)-N' - (2-甲氧基-5-甲基苯基)氨基甲酸酯显示出对sigma2与σ1受体的高亲和力和选择性。 所公开的化合物中有生物素化和荧光类似物。 这些化合物可以作为sigma2受体的探针。 此外,一些公开的化合物可以通过胱天蛋白酶依赖性和半胱天冬酶非依赖性机制诱导凋亡细胞死亡,并且对于治疗肿瘤是有效的。 这些化合物可用作化学治疗剂或化学敏化剂,用于治疗各种实体瘤。
    • 3. 发明申请
    • THERAPEUTIC USES OF BICYCLIC LIGANDS OF SIGMA 2 RECEPTOR
    • SIGMA 2受体的双相配体的治疗用途
    • US20100048614A1
    • 2010-02-25
    • US12543647
    • 2009-08-19
    • Robert H. MachRichard HotchkissWilliam HawkinsRebecca AftZhude Tu
    • Robert H. MachRichard HotchkissWilliam HawkinsRebecca AftZhude Tu
    • A61K31/439A61P35/00
    • C07D451/14C07D451/02
    • A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.
    • 公开了一系列N-取代的9-氮杂双环[3.3.1]壬烷-3α-基苯基氨基甲酸酯类似物及其制备方法。 描述了它们对西格玛(&sgr。1和&sgr; 2)受体的亲和力。 两种新化合物N-(9-(4-氨基丁基)-9-氮杂双环[3.3.1]壬烷-3α-基)-N' - (2-甲氧基-5-甲基苯基)氨基甲酸酯和N-(9- 6-氨基己基)-9-氮杂双环[3.3.1]壬烷-3α-基)-N' - (2-甲氧基-5-甲基苯基)氨基甲酸酯显示出对于& 1受体。 所公开的化合物中有生物素化和荧光类似物。 这些化合物可以作为第二受体的探针。 此外,一些公开的化合物可以通过胱天蛋白酶依赖性和半胱天冬酶非依赖性机制诱导凋亡细胞死亡,并且对于治疗肿瘤是有效的。 这些化合物可用作化学治疗剂或化学敏化剂,用于治疗各种实体瘤。
    • 4. 发明申请
    • Sigma 2 Receptor Ligands and Therapeutic Uses Therefor
    • Sigma 2受体配体及其治疗用途
    • US20080161343A1
    • 2008-07-03
    • US11776533
    • 2007-07-11
    • Robert H. MachZhude TuWenhua ChuSuwanna VangveravongRichard HotchkissWilliam HawkinsRebecca Aft
    • Robert H. MachZhude TuWenhua ChuSuwanna VangveravongRichard HotchkissWilliam HawkinsRebecca Aft
    • A61K31/439C07D453/02C12N5/06A61P35/00
    • C07D451/14C07D451/02
    • A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.
    • 公开了一系列N-取代的9-氮杂双环[3.3.1]壬烷-3-基苯基氨基甲酸酯类似物及其制备方法。 描述了它们对西格玛(sigma1和sigma2)受体的亲和力。 两种新化合物N-(9-(4-氨基丁基)-9-氮杂双环[3.3.1]壬-3α-基)-N' - (2-甲氧基-5-甲基苯基)氨基甲酸酯和N-(9- 6-氨基己基)-9-氮杂双环[3.3.1]壬-3α-基)-N' - (2-甲氧基-5-甲基苯基)氨基甲酸酯显示出对sigma2与σ1受体的高亲和力和选择性。 所公开的化合物中有生物素化和荧光类似物。 这些化合物可以作为sigma2受体的探针。 此外,一些公开的化合物可以通过胱天蛋白酶依赖性和半胱天冬酶非依赖性机制诱导凋亡细胞死亡,并且对于治疗肿瘤是有效的。 这些化合物可用作化学治疗剂或化学敏化剂,用于治疗各种实体瘤。
    • 7. 发明申请
    • Methods and Compositions for Treatment of Sepsis
    • 脓毒症治疗方法和组成
    • US20090012025A1
    • 2009-01-08
    • US12029412
    • 2008-02-11
    • Richard HotchkissJonathan McDunnDavid Piwnica-WormsSteven Schwulst
    • Richard HotchkissJonathan McDunnDavid Piwnica-WormsSteven Schwulst
    • A61K31/7105A61P31/04
    • A61K47/6455A61K47/64A61K47/645
    • Methods of treatment of sepsis are disclosed. These methods comprise administering to a subject a composition comprising at least one siRNA directed against at least one gene encoding a pro-apoptotic polypeptide. The pro-apoptotic polypeptide, in some aspects, can be other than Fas or caspase-8. In some embodiments, an siRNA can be directed against a pro-apoptotic component of the mitochondrial pathway, such as a pro-apoptotic bcl-2 protein. In some aspects, an siRNA can be directed against a BH3-only bcl-2 protein, while in other aspects, siRNAs can be directed against multi BH domain Bcl-2 family members such as bax and bak. In some embodiments, an siRNA can be directed against a death receptor pathway molecule such as FADD. In various configurations, a composition can also comprise a cationic lipid such as DOTAP, or nanoparticles comprising a cyclodextrin-containing polycation and a polymer such as a poly(ethylene glycol).
    • 公开了治疗败血症的方法。 这些方法包括向受试者施用包含针对至少一种编码促细胞凋亡多肽的基因的至少一种siRNA的组合物。 促凋亡多肽在某些方面可能不同于Fas或caspase-8。 在一些实施方案中,siRNA可以针对线粒体途径的促凋亡组分,例如促细胞凋亡的bcl-2蛋白。 在一些方面,siRNA可以针对仅BH3的bcl-2蛋白,而在其它方面,siRNA可以针对多BH结构域Bcl-2家族成员,例如bax和bak。 在一些实施方案中,siRNA可以针对死亡受体途径分子如FADD。 在各种构型中,组合物还可以包含阳离子脂质,例如DOTAP,或包含含环糊精的聚阳离子和聚合物如聚(乙二醇)的纳米颗粒。